LAVA-1207 is a monoclonal antibody commercialized by LAVA Therapeutics, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of LAVA-1207’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for LAVA-1207 is expected to reach an annual total of $13 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
LAVA-1207 is under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is administered through intravenous route. The therapeutic candidate comprises single domain bi-specific antibody that acts by targeting T cell receptor of Vgamma9Vdelta2 T-cells and PSMA. It is being developed based on bi-specific gamma delta T cell engager (bsTCEs) platform and Gammabody platform.
LAVA Therapeutics Overview
LAVA Therapeutics is a biotechnology company. It is engaged in developing immune oncology biopharmaceuticals products. Its proprietary V?9Vd2 T-cell engager candidates bind to the conserved (monomorphic) T-cell receptor of V?9Vd2 T-cells which exhibit potent cytotoxicity, interferon-gamma secretion and HLA-unrestricted tumor cell killing capabilities for alpha-beta-T cells advancing the development of adaptive immune responses for selected tumor targets. Lava Therapeutics licenses its V?9Vd2 T-cell immune oncology assets from the VU University Medical Center in Amsterdam. It seeks to work in partnerships or collaborations in licensing its products and proprietary technologies. The company is funded by Biox Biosciences BV, and Lupus Ventures BV. Lava Therapeutics is headquartered in s-Hertogenbosch, Noord Brabant, the Netherlands.
The company reported revenues of (US Dollars) US$19.4 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$5 million in FY2021. The operating loss of the company was US$34.8 million in FY2022, compared to an operating loss of US$44.4 million in FY2021. The net loss of the company was US$31.9 million in FY2022, compared to a net loss of US$45.4 million in FY2021.
For a complete picture of LAVA-1207’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.